Does anyone follow this stock?
This company is in trial stages of an embryonic stem cell, or some offshoot of embryonic stem cell, technology where they are attempting to treat, postpone or cure age related dry macular degeneration. To my knowledge, there is no treatment for this. I've watched this for a few months and it appears that their CEO has had some shady dealings with not reporting his stock trading and some pretty poorly executed financing deals, some of which are still in tied up in court.
With all that, there appears to be a potential huge upside. They have a great scientist and are performing the trials in some of the best hospitals. The market for dry MD is hundreds of millions of patients. The company regeneron which treats wet MD, ~25% of the MD market, has a market cap of $26B. So far the only results from trials that have been publicized were one patient going from 20/400 to 20/40.
Was just curious if anyone had followed this company or had an opinion on it.
This post was edited on 7/29 at 11:25 am